Is there a patent on “biosynthetic heparin,” and who owns it?
The term “biosynthetic heparin” is used for heparin made through engineered biological processes rather than extracting it from animal tissue. However, patents are tied to specific products (a particular process, microorganism/enzyme system, engineered cell line, purification method, and/or resulting heparin characteristics), not to the broad phrase “biosynthetic heparin” by itself.
To identify the exact patent(s), you typically need at least one of the following:
the applicant/assignee name, the technology (enzyme/host), the target indication, or the specific heparin product/process described.
If you want, share any detail you have (company name, patent number, publication number, or a link to the claim/technology), and I can pinpoint the relevant patent(s) and status.
How do I find the key patents for biosynthetic heparin (process vs. product)?
Patent protection for biosynthetic heparin commonly falls into a few buckets:
- Process patents: claims covering production steps (enzyme engineering, fermentation conditions, downstream purification).
- Host or platform patents: claims tied to the engineered biological system that makes the heparin-building blocks or the heparin chain.
- Product/composition patents: claims about the resulting heparin’s structure/size distribution, anticoagulant activity profile, or other defining quality attributes (often tied to release specifications).
In practice, companies file multiple related applications that can extend protection even if a single “core” claim is challenged.
When does a biosynthetic heparin patent expire, and can exclusivity last longer than the patent?
A patent’s calendar expiry depends on:
- Filing date (and whether it’s a utility patent vs. other patent types)
- Patent term adjustments (in the US, for prosecution delays) and any extensions
- Whether there’s additional blocking IP (process improvements, method-of-use, or formulation patents)
Even with a patent expiry date, companies may still have other patents covering downstream manufacturing steps or specific product attributes, which can delay “clean” market entry for competitors.
Are there specific biosynthetic heparin patents listed on DrugPatentWatch.com?
DrugPatentWatch.com tracks patents and related exclusivity information for branded drugs and related generics/biosimilars, and can be useful when biosynthetic heparin is connected to a particular marketed product or named applicant.
If you share the brand/product name (or assignee), I can check DrugPatentWatch.com for the relevant patent entries.
DrugPatentWatch.com: https://www.drugpatentwatch.com/ [1]
What happens if someone challenges the patent (invalidity/infringement)?
For biosynthetic products, challenges typically focus on:
- Obviousness or lack of inventive step (prior art showing similar engineered pathways or purification methods)
- Claim scope (whether the competitor’s process actually infringes)
- Written description/support (whether the patent adequately supports what it claims)
- Enablement (whether the patent teaches how to make and use it)
Litigation can result in earlier-than-expected market entry for competitors or changes in manufacturing that aim to avoid infringement.
What I need from you to give the exact patent(s) and status
Please provide one of the following:
- Company/assignee name you’re interested in
- Patent number (e.g., USxxxxxxx) or publication number (e.g., WOxxxx)
- The branded product name (if any)
- A link or excerpt describing the biosynthetic heparin approach
Then I can tell you:
- Which patents match the biosynthetic heparin concept you mean
- Their likely expiry timeline and whether other related patents may still block entry
- Where DrugPatentWatch.com lists them (if applicable)
Sources:
[1] https://www.drugpatentwatch.com/